Objectives: Enteroaggregative Escherichia coli (EAEC) and enterotoxigenic E. coli (ETEC) are among the most frequent microorganisms causing traveller's diarrhoea. The aim of this study was to investigate the evolution of antimicrobial resistance in EAEC and ETEC causing diarrhoea in patients who had travelled to different developing countries, comparing two periods of time, 1994-97 and 2001-04.
Introduction
Traveller's diarrhoea is the most frequent health problem among visitors to developing countries. Enteroaggregative Escherichia coli (EAEC) and enterotoxigenic E. coli (ETEC) are a wellrecognized cause of this syndrome in our hospital. 1 Most enteric infections causing diarrhoea do not require antimicrobial therapy. However, in some infections treatment with an antimicrobial agent shortens the duration of shedding in faeces. This could be the case in persistent traveller's diarrhoea caused by EAEC. In severe traveller's diarrhoea, early treatment with loperamide and an antibiotic such as trimethoprim/sulfamethoxazole, doxycycline or a fluoroquinolone has been recommended. 2 In our experience 35% of the patients attending the Tropical Medicine Unit of our hospital with traveller's diarrhoea caused by EAEC or ETEC need antimicrobial therapy due to the severity or the persistence of the symptoms. 3, 4 Fluoroquinolones are potent antimicrobial agents used for the treatment and prophylaxis of infections caused by Gramnegative bacteria, including E. coli. Fluoroquinolone-resistant E. coli has been increasingly reported during the last decade in both the hospital environment and the community, which may ultimately limit the utility of these broad-spectrum agents. 5 Moreover, fluoroquinolone-resistant E. coli strains often show resistance to other drugs, such as ampicillin, tetracycline, chloramphenicol, trimethoprim/sulfamethoxazole and gentamicin. Resistance to quinolones is chromosomal in origin and it is typically caused by mutations in gyrA that result in amino acid substitutions in the GyrA subunit of DNA gyrase. Mutations in the genes encoding the b subunit of DNA gyrase (gyrB) and the gene encoding the a subunit of topoisomerase IV ( parC) have also been reported. Other mechanisms, such as a decrease in drug permeability and active efflux mechanisms, and the most recently described plasmid-mediated mechanisms, can also contribute to quinolone resistance. 5 The aim of this study was to investigate the evolution of antimicrobial resistance in EAEC and ETEC causing diarrhoea in patients who had travelled to different tropical and subtropical countries, in contrast to other published studies, which were restricted to certain geographical areas. In addition, the mechanisms of resistance to quinolones associated with mutations in the gyrA and parC genes have been studied.
Materials and methods

Bacteria
Two different groups of EAEC and ETEC clinical isolates causing traveller's diarrhoea were investigated in this study. The first group was collected from 1994 to 1997, whereas the second group was collected from 2001 to 2004. These strains were isolated from patients who were travellers and had diarrhoea at the time they were seen at the Tropical Medicine Unit in our hospital. None of the patients were admitted. They completed an epidemiologic questionnaire, their clinical history was taken and a physical examination was performed. However, no previous history of antibiotic treatment/prophylaxis was available. Traveller's diarrhoea was defined as the occurrence of three or more episodes of watery stool within a 24 h period, with or without other symptoms, or the occurrence of unformed stools accompanied by one of the following: vomiting, nausea, abdominal cramps, fever, chills, prostration or tenesmus. Persistent diarrhoea was defined as that of .14 days duration. The samples were collected during the acute phase of diarrhoea and were processed within 2 h of collection. The stool specimens were cultured for E. coli and other bacterial enteropathogens by conventional methods. Single colony subcultures of all different lactose-fermenting colonial morphotypes growing on MacConkey agar were identified by conventional criteria. These colonies were tested by PCR to detect EAEC and ETEC as described elsewhere. 6 The use of PCR to detect EAEC was validated in our laboratory using the HEp-2 adherence assay as the reference method. 7 
Susceptibility testing
The MICs of ampicillin, chloramphenicol, nalidixic acid, tetracycline, trimethoprim/sulfamethoxazole, ciprofloxacin and amoxicillin/clavulanic acid were determined by the Etest method according to CLSI guidelines.
8 E. coli ATCC 25922, E. coli ATCC 35218 and Pseudomonas aeruginosa ATCC 27853 were used as controls. The CLSI and EUCAST breakpoints were used to define resistance to nalidixic acid and ciprofloxacin, respectively.
Detection of mutations in the quinolone resistance-determining regions of the gyrA and parC genes by PCR and DNA sequencing
To determine the quinolone resistance mechanisms, mutations in the gyrA and parC genes were detected by PCR performed as described elsewhere. 9, 10 The purified PCR products visualized in gels were processed for DNA sequencing and analysed in an automatic DNA sequencer (ABI 377; Perkin-Elmer, Emeryville, CA, USA) using the BigDye terminator cycle sequencing kit (v3.1; Perkin-Elmer).
Detection of the qnr genes
Screening for the qnrA, qnrB and qnrS genes was performed by multiplex PCR, using a combination of specific primers. 11 Bacterial strains positive for each qnr gene were used as positive controls and were run in each batch of tested samples.
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Results
Fifty EAEC clinical isolates (4.0%) and 82 ETEC clinical isolates (6.5%) were the cause of diarrhoea in 1260 travellers in the first period studied (1994 -97), while EAEC and ETEC strains were identified in 84 (5.1%) patients and 108 (6.5%) patients, respectively, from 1660 patients with travellers' diarrhoea from 2001 -04. In some of these patients other microorganisms, such as Shigella spp. (5 cases), Campylobacter spp. (3 cases), Aeromonas spp. (1 case), Giardia lamblia (9 cases), Entamoeba spp. (10 cases) and Blastocystis hominis (6 cases) were isolated.
The antimicrobial susceptibilities of EAEC and ETEC over the two time periods are shown in Table 1 . Taking both study periods together, the highest levels of resistance in EAEC were found for tetracycline (70%), ampicillin (57%) and trimethoprim/sulfamethoxazole (52%), followed by chloramphenicol (37%), nalidixic acid (12%), amoxicillin plus clavulanic acid (10.5%) and ciprofloxacin (3%). In ETEC the highest levels of resistance were found for trimethoprim/sulfamethoxazole (58.5%), tetracycline (58%) and ampicillin (48%), followed by chloramphenicol (25.5%), nalidixic acid (14%), amoxicillin/ clavulanic acid (9%) and ciprofloxacin (4.5%) ( Table 1) . However, if the resistance of EAEC and ETEC isolates to various antimicrobial agents is compared between the two periods of time, a statistically significant increase in resistance (P, 0.01) was observed in EAEC for chloramphenicol and amoxicillin plus clavulanic acid, whereas in ETEC it was for trimethoprim/sulfamethoxazole, nalidixic acid, ciprofloxacin and amoxicillin/clavulanic acid (Table 1) .
In E. coli, a higher quinolone resistance level has been related to the presence of concomitant mutations in the gyrA and parC genes. In the strains isolated from the period 2001 -04, it was observed that 10 (77%) out of the 13 quinolone-resistant EAEC isolates showed a phenotype characterized by resistance to nalidixic acid and susceptibility to ciprofloxacin that was indicative of mutations in the gyrA and/or parC genes. In all but one of these isolates, a mutation in the amino acid codon Ser-83 of the gyrA gene was found, which produced a change from Ser to Leu in GyrA. The remaining isolate showed a change from Ser to Ala in GyrA. Three EAEC isolates presented a phenotype of resistance to both nalidixic acid and ciprofloxacin associated with mutations in the gyrA and parC genes ( Table 2 ). Ten out of the 11 travellers with diarrhoea caused by quinolone-resistant EAEC had travelled to India. Thirteen (54%) ETEC isolates showed resistance to nalidixic acid and susceptibility to ciprofloxacin, which was associated with a Ser-83 substitution in GyrA, whereas 11 (46%) showed resistance to both quinolones, which was related to two, three or four mutations in the gyrA and parC genes (Table 3) . Sixteen (73%) out of the 22 travellers in which a quinolone-resistant ETEC was detected had travelled to India. The prevalence of quinolone-resistant EAEC and ETEC was high among the isolates from patients who had travelled to North Africa (50% of EAEC and 43% of EAEC were resistant to quinolones) and among the isolates from patients who had travelled to the Indian subcontinent (66% of EAEC and 64% of ETEC were resistant to quinolones). In addition, 33% of the ETEC strains from patients travelling to South-east Asia were also quinolone resistant (Table 4) .
Discussion
Antimicrobial resistance in human pathogenic bacteria is a global public health problem. The high levels of resistance of EAEC and ETEC to antimicrobial agents such as ampicillin, tetracycline, chloramphenicol and trimethoprim/sulfamethoxazole observed in this study is likely associated with the use and abuse of these inexpensive, first-line, broad-spectrum antimicrobial agents in developing countries. In both EAEC and ETEC, a significant increase has been observed between the two periods of time studied for amoxicillin plus clavulanic acid. This increase in resistance may be associated with the acquisition of a plasmid-mediated OXA-type b-lactamase, which is less inhibited by clavulanic acid, or the overexpression of the TEM-type b-lactamase (investigation in progress). In addition, an increase has been observed in resistance to quinolones in EAEC and ETEC. In both EAEC and ETEC, the predominant phenotype of resistance to quinolones is characterized by resistance to nalidixic acid and susceptibility to ciprofloxacin, which may be explained by the presence of a unique mutation in the gyrA gene. However, the range of MIC of nalidixic acid for this group of isolates went from 32 to 1048 mg/L, which can be explained by a concomitant mechanism of resistance to quinolones in the isolates with the higher resistance, such as overexpression of the AcrAB-TolC efflux pump. The qnr genes were not detected in any of the quinolone-resistant isolates (data not shown).
This increase in quinolone resistance has previously been described for Campylobacter spp. and mainly from travellers to Asia. 13 Moreover, in recent studies, a similar trend has been observed in Salmonella spp. and Shigella spp. causing traveller's diarrhoea, with a steady increase in the past 5 years. 14, 15 The main geographical area from which quinolone-resistant Salmonella and Shigella strains were isolated was also India. In our study, nalidixic acid-resistant ETEC in strains isolated from patients returning from India has increased from 6% in the period 1994 -97 to 64% in the period 2001 -04. Nalidixic acid was introduced a decade ago as first-line therapy for shigellosis in some areas of this country, and therefore EAEC and ETEC strains resistant to nalidixic acid are now present.
In various reports antimicrobial agents have been shown to reduce the symptomatic duration of traveller's diarrhoea. Treatment recommendations must evolve in relation to antimicrobial resistance. In this study we have seen a high prevalence of isolates resistant to 'classical' antimicrobial agents such as tetracycline, trimethoprim/sulfamethoxazole (co-trimoxazole) and chloramphenicol, which leads to these previous empirical therapy choices not being recommended. Although other alternatives such as rifaximin have been provided, 16 fluoroquinolones are still being recommended as empirical antibiotic therapy for traveller's diarrhoea. 17 Although ciprofloxacin was the first fluoroquinolone used for traveller's diarrhoea treatment, other fluoroquinolones such as norfloxacin, ofloxacin or levofloxacin have shown similar efficacy. 18 -20 In summary, EAEC and ETEC strains are a frequent cause of traveller's diarrhoea requiring antimicrobial therapy. The resistance of these microorganisms to the classical agents such as trimethoprim/sulfamethoxazole, tetracycline and ampicillin is very high due to the widespread use of these antimicrobial agents in tropical and subtropical countries. Fluoroquinolones are the drugs of choice for travellers to take with them when travelling to high-risk areas or the drugs of choice to be prescribed to travellers returning from these areas. However, the high percentage of resistance to quinolones in ETEC and EAEC isolated from travellers to North Africa and India is a matter for concern. These agents should therefore be used with caution in patients with traveller's diarrhoea coming from these geographical areas. 
